Crobenetine

Drug Profile

Crobenetine

Alternative Names: BIII-890; BIII-890-CL

Latest Information Update: 13 Nov 2014

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-ischaemics; Benzomorphans; Neuroprotectants; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain; Stroke

Most Recent Events

  • 17 Apr 2009 Discontinued - Phase-II for Stroke in Germany and Spain (IV)
  • 17 Apr 2009 Discontinued - Preclinical for Pain in Germany (IV)
  • 08 Aug 2003 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top